How Lithium Prevents Suicide
Lithium is effective at lowering the risk of suicide in individuals with mood disorders, independent of its mood-stabilizing effect, through mechanisms that include reducing aggression, impulsivity, and dysphoric mood, particularly via its effects on the serotonergic system. 1
Mechanism of Action
Lithium's anti-suicide effects appear to operate through multiple pathways beyond simply treating mood episodes:
- Serotonergic modulation: Lithium enhances central serotonin function, which directly impacts the "impulsive-aggressive" endophenotype strongly associated with suicidal behavior in bipolar disorder 2
- Reduction of impulsivity and aggression: The drug specifically targets impulsive and aggressive behaviors that are vulnerability factors for suicide, independent of its effects on mood stabilization 1, 3, 4
- Stress response regulation: Lithium appears to regulate responses to stress and reduce agitation, which are critical factors in acute suicidal crises 1
The FDA label notes that lithium "alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines," though the specific biochemical mechanism remains incompletely understood 5.
Clinical Evidence for Suicide Prevention
The evidence for lithium's anti-suicide effects is robust:
Magnitude of benefit: Long-term lithium maintenance treatment reduces suicide attempts by approximately 93% and completed suicides by 82% compared to no lithium treatment 6. Meta-analyses show lithium reduces all suicidal acts from 3.10 per 100 person-years without treatment to 0.21 with lithium—bringing rates close to general population levels 6.
Comparison to other treatments: Lithium demonstrates an 8.6-fold reduction in recurrence of suicide attempts in adults with bipolar or major affective disorders 2. When lithium is discontinued, there is a 7-fold increase in suicide attempts and 9-fold increase in completed suicide 2.
Diagnostic specificity: The protective effect appears strongest in unipolar depression (100% risk reduction), followed by bipolar II disorder (82%), and bipolar I disorder (67%) 6. This hierarchy suggests lithium may be particularly effective when depressive features predominate.
Clinical Application
For bipolar disorder: Lithium is FDA-approved for acute mania and maintenance therapy (down to age 12 years) 7, 5. The 2024 systematic review emphasizes that treatment algorithms should guide timely introduction of lithium in both unipolar and bipolar disorders when clinically indicated 1.
Critical treatment factors:
- Maintain lithium blood concentrations in the therapeutic range—subtherapeutic levels negate the anti-suicide benefit 4
- Long-term treatment is essential; the protective effect requires sustained exposure averaging 3.36 years in pooled studies 6
- Combination with antidepressants may reduce suicidal ideation prior to improvement in depressive symptoms 4
Important caveat: The 2025 VA/DoD guidelines note there is now "insufficient evidence to recommend for or against lithium to reduce the risk of suicide or suicide attempts for patients with mood disorders" (downgraded from "weak for" in 2019) 8. However, this reflects the challenges of conducting randomized controlled trials for suicide outcomes rather than negating the substantial observational evidence. The most recent 2025 meta-analysis of RCTs showed nonsignificant trends favoring lithium (OR = 0.73 for attempts, OR = 0.61 for completed suicide), likely representing type II error from small sample sizes 9.
Safety Considerations
Overdose risk: Lithium prescriptions for children and adolescents require careful third-party supervision, as overdoses may be lethal 2. This is a critical distinction from SSRIs, which have low lethal potential in overdose 2.
Monitoring requirements: Patients must maintain normal diet including salt and adequate fluid intake (2500-3000 mL) during stabilization 5. Decreased tolerance occurs with protracted sweating, diarrhea, or fever—requiring temporary dose reduction or supplemental fluids 5.
When to Prioritize Lithium
Consider lithium as first-line when:
- Patient has bipolar disorder with history of suicidal ideation or attempts
- Prominent impulsivity, aggression, or dysphoric/mixed features are present
- Treatment-resistant depression with recurrent major depressive disorder
- Patient can commit to therapeutic drug monitoring and long-term adherence
The anti-suicide effect is unique to lithium among mood stabilizers—other agents like valproate and carbamazepine lack this specific benefit despite efficacy for mood stabilization 2, 4.